Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shar...
February 15 2018 - 4:02PM
Heidelberg, Germany, February 15, 2018 - Affimed
N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company
focused on discovering and developing highly targeted cancer
immunotherapies, today announced the closing of its previously
announced public offering of 13,225,000 of its common shares at a
public offering price of $2.00 per common share. The total
includes 1,725,000 common shares issued pursuant to the
underwriters' option to purchase additional shares. After
deducting the underwriting discounts and other estimated offering
expenses, the net proceeds of the public offering are expected to
be approximately $24.5 million.
Jefferies LLC and Wells Fargo Securities, LLC
are acting as joint book-running managers.
A shelf registration statement relating to these
securities filed with the Securities and Exchange Commission (SEC)
was declared effective by the SEC on October 23, 2015. The offering
was made only by means of a prospectus and prospectus supplement. A
prospectus supplement and accompanying prospectus related to the
offering have been filed with the SEC and are available at the
SEC's website located at www.sec.gov. Copies of the prospectus
supplement and accompanying prospectus related to the offering may
be obtained by contacting Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor,
New York, NY 10022, or by telephone at 877-547-6340, or
by email at Prospectus_Department@Jefferies.com, or Wells Fargo
Securities, LLC, Attention: Equity Syndicate Department, 375 Park
Avenue, New York, NY 10152, or by telephone at (800) 326-5897, or
by email at cmclientsupport@wellsfargo.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of, these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Affimed N.V.Affimed
(Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure
patients by harnessing the power of innate and adaptive immunity
(NK and T cells). We are developing single and combination
therapies to treat cancers and other life-threatening diseases.
FORWARD-LOOKING STATEMENTSThis
press release contains forward-looking statements. All statements
other than statements of historical fact are forward-looking
statements, which are often indicated by terms such as
"anticipate," "believe," "could," "estimate," "expect," "goal,"
"intend," "look forward to", "may," "plan," "potential," "predict,"
"project," "should," "will," "would" and similar expressions.
Forward-looking statements appear in a number of places throughout
this release and include statements regarding our intentions,
beliefs, projections, outlook, analyses and current expectations
concerning, among other things, the safety and efficacy of our
product candidates, our ongoing and planned preclinical development
and clinical trials, our collaborations and development of our
products in combination with other therapies, the timing of and our
ability to make regulatory filings and obtain and maintain
regulatory approvals for our product candidates our intellectual
property position, our collaboration activities, our ability to
develop commercial functions, expectations regarding clinical trial
data, our results of operations, cash needs, financial condition,
liquidity, prospects, future transactions, growth and strategies,
the industry in which we operate, the trends that may affect the
industry or us and the risks uncertainties and other factors
described under the heading "Risk Factors" in Affimed's filings
with the Securities and Exchange Commission. Given these risks,
uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future.
Contact: Anca Alexandru, Head of Communications, EU IR Phone:
+49 6221 64793341 E-Mail: a.alexandru@affimed.com,
IR@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024